For the quarter ending 2025-09-30, VRCA had $5,701K increase in cash & cash equivalents over the period. $9,685K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 30,485 | - |
| Selling, general and administrative | 27,103 | - |
| Research and development | 6,335 | - |
| Cost of revenue | 2,040 | - |
| Other segment items | 4,819 | - |
| Net loss | -9,812 | - |
| Depreciation expense | - | 100 |
| Stock-based compensation | 718 | 1,914 |
| Depreciation expense | 19 | 100 |
| Non-cash interest expense | 716 | 1,359 |
| Loss on disposal of fixed assets | -68 | -178 |
| Net loss | - | -9,538 |
| Loss on termination of financing lease | 1 | -4 |
| Amortization of operating lease right-of-use asset | 74 | 146 |
| Amortization of finance lease right-of-use asset | 87 | 165 |
| Non-cash accretion of r&d funding liability | 375 | - |
| Change in fair value of derivative liability | 34 | 852 |
| Prepaid expenses and other assets | 2,094 | -818 |
| Collaboration receivable, billed and unbilled | -7,896 | 8,149 |
| Inventory | -218 | 59 |
| Accounts payable | -736 | 425 |
| Deferred revenue | 1,564 | 481 |
| Accounts receivable | -2,146 | 9,145 |
| Accrued expenses and other current liabilities | -501 | -410 |
| Operating lease liability | -79 | -154 |
| Net cash used in operating activities | 9,685 | -22,721 |
| Purchases of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from exercise of stock options | 0 | 0 |
| Payment of debt amendment fees | 0 | 0 |
| Repayment of debt | 3,890 | 8,029 |
| Repayment of finance lease | 94 | 183 |
| Payment of equity issuance costs | 0 | - |
| Net cash used in financing activities | -3,984 | -8,212 |
| Net decrease in cash and cash equivalents | 5,701 | -30,933 |
| Cash and cash equivalents at beginning of period | 46,329 | - |
| Cash and cash equivalents at end of period | 21,097 | - |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)